Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Ligand Pharmaceuticals Incorporated - Common Stock (NQ:LGND)

289.61 -3.65 (-1.24%)
Delayed Quote Updated: 1:37 PM EDT, Oct 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ligand Pharmaceuticals Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Ligand Pharmaceuticals (NASDAQ:LGND) Flashes Strong Trend and High-Growth Momentum Despite Setup Caution ↗
Via Chartmill
News headline image
If You Invested $100 In Ligand Pharmaceuticals Stock 5 Years Ago, You Would Have This Much Today ↗
Ligand Pharmaceuticals (NASDAQ:LGND) has outperformed the market over the past 5 years by 17.28% on an annualized basis producing an average annual return of 28.4%. Currently, Ligand Pharmaceuticals... 
Via Benzinga
News headline image
Ligand Pharmaceuticals Highlights XOMA-Fueled Royalty Growth, $700M in Deployable Capital ↗
Ligand Pharmaceuticals (NASDAQ:LGND) outlined its royalty-focused growth strategy, recent XOMA acquisition and portfolio catalysts during a company presentation, highlighting a larger commercial-stage... 
Via MarketBeat
News headline image
$100 Invested In Ligand Pharmaceuticals 10 Years Ago Would Be Worth This Much Today ↗
Ligand Pharmaceuticals (NASDAQ:LGND) has outperformed the market over the past 10 years by 2.79% on an annualized basis producing an average annual return of 16.18%. Currently, Ligand Pharmaceuticals... 
Via Benzinga
News headline image
Ligand (LGND) Q2 2026 Earnings Call Transcript ↗
XOMA acquisition and convertible financing boost 2026 guidance to $9.00–$9.50 per share. 
Via The Motley Fool
Topics Earnings
Ligand Pharmaceuticals (NASDAQ:LGND) Beats Q2 EPS Estimates, Shares Flat on In-Line Revenue ↗
Via Chartmill
News headline image
Ligand Pharmaceuticals Q2 Earnings Call Highlights ↗
Ligand Pharmaceuticals (NASDAQ:LGND) reported second-quarter 2026 results marked by higher royalty revenue and adjusted earnings, while highlighting the post-quarter close of its XOMA Royalty... 
Via MarketBeat
Topics Earnings
News headline image
$100 Invested In Ligand Pharmaceuticals 15 Years Ago Would Be Worth This Much Today ↗
Ligand Pharmaceuticals (NASDAQ:LGND) has outperformed the market over the past 15 years by 14.91% on an annualized basis producing an average annual return of 28.27%. Currently, Ligand Pharmaceuticals... 
Via Benzinga
News headline image
Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets
From Ligand Pharmaceuticals
Via GlobeNewswire
News headline image
XOMA Royalty Announces Closing of Its Acquisition by Ligand
From XOMA Royalty Corporation
Via GlobeNewswire
Ligand Pharmaceuticals (NASDAQ:LGND) Shares Fall on Q1 Revenue and EPS Miss ↗
Via Chartmill
Ligand Pharmaceuticals (NASDAQ:LGND) Passes Minervini Trend Template and Growth Screen ↗
Via Chartmill
News headline image
3 Overlooked Stocks Positioned for the Next Market Rotation ↗
Oxford Club strategist Marc Lichtenfeld highlights diversification beyond tech, spotlighting Ligand Pharmaceuticals, Aflac and Atlantic Union Bankshares as healthcare, insurance and banking stocks... 
Via MarketBeat
Topics Artificial Intelligence
News headline image
Ligand Pharmaceuticals Director Unloads 2,501 Shares — Should You Be Concerned? ↗
This biotech innovator, known for its royalty-driven model, reported a notable insider sale amid a period of strong share price gains. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
A Ligand Pharmaceuticals (LGND) Insider Sold 5,000 Shares for $1.1 Million ↗
Biotech royalty player Ligand Pharmaceuticals reported a notable insider sale following a year of strong stock performance. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Wealth Manager Sells $7 Million of Establishment Labs After Massive Gains. Is This Medical Device Stock a Buy? ↗
Establishment Labs develops advanced silicone implants and medical devices for global plastic surgery markets. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
OneSpaWorld Posted Record Revenue for Last Quarter. Why Did a Fund Exit a $21.5 Million Stake? ↗
OneSpaWorld provides spa, fitness, and beauty services to cruise and resort guests through exclusive wellness partnerships worldwide. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Is Genpact Stock a Buy After Hedge Fund Rice Hall James Raised Its Stake by $14 Million? ↗
Genpact delivers business process and IT services to global enterprises, with a diversified client base across multiple industries. 
Via The Motley Fool
Topics Artificial Intelligence Economy
News headline image
Is WaterBridge Stock a Buy After Ranger Investment Raised Its Stake by 345,000 Shares? ↗
WaterBridge Infrastructure delivers water management and recycling services to oil and gas producers across major U.S. shale basins. 
Via The Motley Fool
Topics Initial Public Offering
News headline image
Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Ligand (LGND) Q1 2026 Earnings Call Transcript ↗
Ligand (LGND) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Ligand Pharmaceuticals Q1 Earnings Call Highlights ↗
Ligand Pharmaceuticals (NASDAQ:LGND) reported first-quarter 2026 results that management said reflect the operating leverage of its royalty aggregation strategy, highlighted by growing royalties from... 
Via MarketBeat
Topics Earnings
News headline image
Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX), Soleno Therapeutics, Inc. (Nasdaq – SLNO)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Villere St Denis Liquidates $18 Million Euronet Worldwide Stake, According to Recent SEC Filing ↗
Euronet Worldwide encompasses ATM and electronic funds transfer (EFT) services, prepaid distribution, and money transfer, resulting in a more complex structure than that of a typical payments network.... 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Villere St Denis Dumps 134,000 Tidewater (TDW) Shares Worth $9.3 Million ↗
Specializing in offshore marine support, Tidewater serves global energy clients across oil, gas, and windfarm projects. 
Via The Motley Fool
Topics Energy Regulatory Compliance
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX), Soleno Therapeutics, Inc. (Nasdaq – SLNO)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
CLO Sells LGND 5,000 Shares for $1.0 Million ↗
Ligand Pharmaceuticals, a leader in drug licensing and royalties, reported a notable insider sale amid strong recent share performance. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Ligand Pharma CFO Sells $688K in Stock as Shares Surge 80% This Past Year. Here's What to Know ↗
This royalty-focused biotech with a broad drug portfolio reported a notable insider sale amid strong stock performance. 
Via The Motley Fool
Topics Regulatory Compliance
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.